Acadia Pharmaceuticals (NASDAQ:ACAD) is a company whose shares are active, trading 2.6% higher to $5.14. The S&P is trading lower by 0.2% to 1,469 and the Dow is trading fractionally lower to 13,484.
There is potential upside of 62.6% for shares of Acadia Pharmaceuticals based on a current price of $5.14 and an average consensus analyst price target of $8.36. The stock should find initial support at its 50-day moving average (MA) of $3.87 and further support at its 200-day MA of $2.32.
Over the past year, Acadia Pharmaceuticals has traded in a range of $1.24 to $6.54 and is now at $5.14, 315% above that low. Over the past week, the 200-day moving average (MA) has gone up 3.1% while the 50-day MA has advanced 7.4%.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.